Middle East Respiratory Syndrome Coronavirus (MERS-CoV)
Respiratory·MeSH: Coronavirus Infections
Prevalence
0.1 / 100K
1 drug in development·1 company·1 clinical trial
Drug Pipeline by Phase
Phase 2(1)
| Drug | Company |
|---|---|
| ino-4700 | INOVIO PHARMACEUTICALS, INC. (INO) |
Frequently asked questions
How many drugs are in development for Middle East Respiratory Syndrome Coronavirus (MERS-CoV)?
BioSniper tracks 1 drug in development for Middle East Respiratory Syndrome Coronavirus (MERS-CoV) across 1 company.
How many clinical trials target Middle East Respiratory Syndrome Coronavirus (MERS-CoV)?
There are 1 clinical trial targeting Middle East Respiratory Syndrome Coronavirus (MERS-CoV) tracked by BioSniper.
What is the prevalence of Middle East Respiratory Syndrome Coronavirus (MERS-CoV)?
The estimated prevalence of Middle East Respiratory Syndrome Coronavirus (MERS-CoV) is approximately 0.1 per 100,000 population.
Deep-dive into Middle East Respiratory Syndrome Coronavirus (MERS-CoV)
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis